The endoscopic and pathological features of early gastric mixed adenoneuroendocrine carcinoma (MANEC), as well as its carcinogenesis, remain largely unclear. Screening esophagogastroduodenoscopy was performed on an 80-year-old man, revealing 3 superficial elevated lesions. Endoscopic submucosal dissection (ESD) was performed, and the patient was diagnosed with intramucosal gastric cancer comprising mixed adenocarcinoma and neuroendocrine tumor, well-differentiated adenocarcinoma and well-differentiated adenocarcinoma, with negative margins. To our knowledge, this is the first report describing the endoscopic and pathological findings of synchronous triple gastric cancer incorporating mixed adenocarcinoma and neuroendocrine tumor completely resected with ESD.
Introduction
Mixed adenoneuroendocrine carcinoma (MANEC) (1) is a tumor composed of both adenocarcinoma and neuroendocrine carcinoma (NEC) components, with each comprising at least 30% of the lesion. La Rosa et al. (2) classified MANECs into high-grade tumors composed of adenocarcinoma and NEC and intermediate-grade tumors composed of mixed adenocarcinoma and G1/G2 neuroendocrine tumor (NET). The endoscopic and pathological features of early gastric MANEC remain poorly described.
We herein report a case of synchronous triple gastric cancer incorporating MANEC completely resected with endoscopic submucosal dissection (ESD).
Case Report
Screening esophagogastroduodenoscopy (EGD) was performed on an 80-year-old man, revealing 3 superficial elevated lesions in the anterior wall of the middle gastric body, the posterior wall of the gastric angle, and the lesser gastric body (Fig. 1) . The patient was shown to be positive for serum IgG antibody to Helicobacter pylori but negative for anti-parietal cells and anti-intrinsic factor antibodies, suggesting the presence of H. pylori-associated atrophic gastritis.
ESD was performed on suspected well-differentiated tubular adenocarcinoma (Fig. 2) . Histologically, the tumor in the anterior wall showed two distinct components of tubular adenocarcinoma: well-differentiated type (tub1) and NET G1, which represented the major and minor components, respectively, each accounting for >30% of the tumor (Fig. 3) . The NET component, which was positive for chromogranin A (Fig. 4A ), synaptophysin and serotonin (Fig. 4B) , was shown to have infiltrated into the muscularis mucosae (Fig. 5) . The tumor was diagnosed as mixed adenocarcinoma and neuroendocrine tumor, G1.
The patient was thus eventually diagnosed with intramucosal gastric cancer comprising: 1) 0-IIa 25×22 mm mixed (Table) . However, of these, only one was classified as an intramucosal lesion in terms of the histological depth, with the other two classified as submucosal lesions. Therefore, the endoscopic and pathological features of early gastric MANEC remain poorly described. Furthermore, the carcinogenesis of MANEC remains unclear. At least two possible hypotheses have been proposed: 1) the partial differentiation of adenocarcinoma into neuroendocrine cells (8) and 2) the bidirectional transformation of monoclonal pluripotent epithelial stem cells into adenocarcinoma and neuroendocrine cells (9) . In the present case, the components of adenocarcinoma and NET showed a clear tissue distribution but merged into each other at the border. A case of mixed adenocarcinoma and NET G1 of the rectum was recently reported to have likely differentiated from common putative precursor cells bi-directionally at an early stage of tumorigenesis, given the absence of any NET component in the surface epithelium as well as the evidence of monoclonal pluripotent epithelial stem cells (10) . In our case, no NET component was observed at the surface epithelium either, suggesting that gastric mixed adenocarcinoma (tub1) and NET (G1) might have differentiated from monoclonal pluripotent epithelial stem cells. To our knowledge, this is the first report describing the endoscopic and pathological findings of gastric mixed adenocarcinoma and NET G1 completely resected with ESD. The second important clinical issue that emerged in our case is that gastric mixed adenocarcinoma and neuroendocrine tumor may be derived from H. pylori-associated chronic gastritis as well as from gastric cancer. Gastric NETs are categorized into three types: type I, which is associated with autoimmune chronic atrophic gastritis; type II, which is associated with multiple endocrine neoplasia type 1 (MEN 1) and Zollinger-Ellison syndrome; and type III, which is shown to occur sporadically (11) . Recently, type I gastric NET was reported to be associated with excessive gastrin secretion secondary to atrophic gastritis and might be derived from H. pylori-associated chronic gastritis (12) . Reports of type I gastric NET with hypergastrinemia following H. pylori-associated chronic gastritis have also been published (13, 14) . In our case, the patient was shown to be positive for serum IgG antibody to H. pylori but negative for anti-parietal cells and anti-intrinsic factor antibodies, and blood tests 2 months after the withdrawal of vonoprazan revealed hypergastrinemia (gastrin, up to 1,360 pg/mL).
In addition, given that endocrine cell hyperplasia and endocrine cell micronests were not recognized in the background gastric mucosa, hypergastrinemia following H. pylori-associated atrophic gastritis was thought likely to be responsible for the condition. We therefore concluded that synchronous triple gastric cancer incorporating gastric mixed adenocarcinoma and neuroendocrine tumor all developed against a background of H. pylori-associated chronic gastritis. To our knowledge, this is the first report describing gastric mixed adenocarcinoma and type I NET G1 probably derived from H. pylori-associated chronic gastritis.
In conclusion, gastric mixed adenocarcinoma and NET G1 may present as an intramucosal lesion and be derived from H. pylori-associated chronic gastritis as well as from gastric cancer. Further studies are needed in order to determine whether or not gastric mixed adenocarcinoma and NET G1 may arise from H. pylori-associated chronic gastritis.
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